Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Clark, Aaron J ^a   Safaee, Michael ^a   Oh, Taemin ^b   Ivan, Michael E ^a   Parimi, Vamsi ^b   Hashizume, Rintaro ^b   Ozawa, Tomoko ^a   James, Charles D ^b   Bloch, Orin ^b   Parsa, Andrew T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

GL261; Glioma; Immunotherapy; Luciferase; Microenvironment; Mouse model

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CD3 ANTIGEN; CD31 ANTIGEN; FIREFLY LUCIFERASE; INTERLEUKIN 13; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA2; CYTOKINE; LUCIFERASE;

ANIMAL CELL; ARTICLE; BIOLUMINESCENCE; BRAIN REGION; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME MODIFICATION; GLIOMA CELL; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LUMINESCENCE; MEDICAL RESEARCH; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR IMMUNOLOGY; ANIMAL; BRAIN TUMOR; CELL DIVISION; GENETICS; GLIOMA; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CYTOKINES; GLIOMA; LUCIFERASES; MICE;

EID: 84921032976     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0345-4     Document Type: Article

References (22)

1. Crane CA, Ahn BJ, Han SJ, Parsa AT: Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 2012, 14:584-595.
2. Sughrue ME, Yang I, Kane AJ, Rutkowski MJ, Fang S, James CD, Parsa AT: Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med 2009, 7:84.
3. Ausman JI, Shapiro WR, Rall DP: Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 1970, 30:2394-2400.
4. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL: Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000, 88:2606-2618.
5. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH: Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 2003, 49:848-855.
6. Ksendzovsky A, Feinstein D, Zengou R, Sharp A, Polak P, Lichtor T, Glick RP: Investigation of immunosuppressive mechanisms in a mouse glioma model. J Neurooncol 2009, 93:107-114.
7. Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, Fontana A, Suter T: Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol 2009, 39:1323-1333.
8. El Andaloussi A, Han Y, Lesniak MS: Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006, 105:430-437.
9. Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, Zabski S, Yancopoulos GD, Grumet M: Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 2000, 80:837-849.
10. Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N, Lan L, Dewyngaert JK, Zagzag D, McBride WH, Formenti SC: The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res 2006, 12:4730-4737.
11. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, Caldera V, Nava S, Ravanini M, Facchetti F, Bruzzone MG, Finocchiaro G: Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006, 66:10247-10252.
12. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD: Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007, 6:1167-1174.
13. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW: Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 2006, 12:1868-1875.
14. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD: Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg 2007, 107:610-616.
15. Ozawa T, James CD: Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp 2010.
16. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103:1656-1664.
17. Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R, Basso G: BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1alpha stability and MGMT expression. Cell Death Dis 2012, 3:e412.
18. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, Deangelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J: Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol 2013, 8:117-125.
19. Platten M, Wick W, Weller M: Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001, 52:401-410.
20. Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH: Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 2007, 9:259-270.
21. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004, 64:7954-7961.
22. Huang Y, Hoffman C, Rajappa P, Kim JH, Hu W, Huse J, Tang Z, Li X, Weksler B, Bromberg J, Lyden DC, Greenfield JP: Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res 2014, 74:1011-1021.